📣 VC round data is live. Check it out!
- Public Comps
- 908 Devices
908 Devices Valuation Multiples
Discover revenue and EBITDA valuation multiples for 908 Devices and similar public comparables like Profound Medical, Shoulder Innovations, Senseonics Holdings, Healius and more.
908 Devices Overview
About 908 Devices
908 Devices Inc manufactures medical devices. It has developed a suite of purpose-built handheld and desktop mass spectrometry, or Mass Spec, devices for the point-of-need. Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the critical problems in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company geographically derives maximum revenue from United States, and also has its presence in Europe, Middle East and Africa, Americas and Other and Asia Pacific.
Founded
2012
HQ

Employees
71
Website
Financials (LTM)
EV
$157M
Valuation Multiples
Start free trial908 Devices Financials
908 Devices reported last 12-month revenue of $61M and negative EBITDA of ($8M).
In the same LTM period, 908 Devices generated $39M in gross profit, ($8M) in EBITDA losses, and had net loss of ($27M).
Revenue (LTM)
908 Devices P&L
In the most recent fiscal year, 908 Devices reported revenue of $56M and EBITDA of ($10M).
908 Devices is profitable as of last fiscal year, with gross margin of 51%, EBITDA margin of (17%), and net margin of 35%.
Financial data powered by Morningstar, Inc.
908 Devices Stock Performance
908 Devices has current market cap of $265M, and enterprise value of $157M.
Market Cap Evolution
908 Devices' stock price is $7.09.
908 Devices share price increased by 3.8% in the last 30 days, and by 24.8% in the last year.
908 Devices has an EPS (earnings per share) of $0.52.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $157M | $265M | 0.0% | 3.8% | 3.1% | 24.8% | $0.52 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free Trial908 Devices Valuation Multiples
908 Devices trades at 2.6x EV/Revenue multiple, and (18.8x) EV/EBITDA.
EV / Revenue (LTM)
908 Devices Financial Valuation Multiples
As of May 8, 2026, 908 Devices has market cap of $265M and EV of $157M.
908 Devices has a P/E ratio of (9.8x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified 908 Devices Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


908 Devices Margins & Growth Rates
908 Devices grew revenue by 22% but EBITDA decreased by 37% in the last fiscal year.
In the most recent fiscal year, 908 Devices reported gross margin of 51%, EBITDA margin of (17%), and net margin of 35%.
908 Devices Margins
908 Devices Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
908 Devices Operational KPIs
908 Devices' revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $0.8M for the same period.
908 Devices' Rule of 40 is 13% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
908 Devices' Rule of X is 46% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
908 Devices Competitors
908 Devices competitors include Profound Medical, Shoulder Innovations, Senseonics Holdings, Healius, Eurobio Scientific, Australian Clinical Labs, Zepp Health, Frontage Laboratories, Asterasys and TriSalus Life Sciences.
Most 908 Devices public comparables operate across Medical Devices, Laboratory Services, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 13.0x | 9.9x | (5.7x) | (6.1x) | |||
| 3.4x | 3.0x | (4.4x) | (4.8x) | |||
| 5.9x | 4.7x | (3.3x) | — | |||
| 0.9x | 0.9x | 5.8x | 4.7x | |||
| 1.3x | 1.3x | 7.8x | 7.4x | |||
| 0.9x | 0.9x | 3.5x | 3.3x | |||
| 1.7x | 1.5x | (17.0x) | (30.5x) | |||
| 1.3x | 1.3x | 6.4x | 9.6x | |||
This data is available for Pro users. Sign up to see all 908 Devices competitors and their valuation data. Start Free Trial | ||||||
908 Devices Funding History
Before going public, 908 Devices raised $56M in total equity funding, across 4 rounds.
908 Devices Funding Rounds
908 Devices M&A Activity
908 Devices has acquired 2 companies to date.
Last acquisition by 908 Devices was on April 30th 2024. 908 Devices acquired RedWave Technology for $54M (EV/Revenue multiple of ).
Latest Acquisitions by 908 Devices
| Description | RedWave Technology is a provider of portable Fourier Transform Infrared spectrometers for material identification and chemical analysis. The battery-powered devices perform non-destructive testing in hazmat response, forensics, and industrial quality control. RedWave Technology, based in the United States, supplies units to emergency responders and laboratories worldwide. | TRACE Analytics is a German company offering online analysis systems for biopharmaceutical applications. Located in Munich, it provides measurement technologies for gas, liquid, and multiphase flows in research labs, pilot plants, and production facilities. The systems support process analytical technology in biotech fermentation, cell culture monitoring, and downstream processing for vaccine and monoclonal antibody manufacturing. |
| HQ Country | ||
| HQ City | Danbury, CT | Braunschweig |
| Deal Date | 30 Apr 2024 | 9 Aug 2022 |
| Valuation | $54M | $15M |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all 908 Devices acquisitions and their M&A valuation multiples. Start Free Trial | ||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout 908 Devices
| When was 908 Devices founded? | 908 Devices was founded in 2012. |
| Where is 908 Devices headquartered? | 908 Devices is headquartered in United States. |
| How many employees does 908 Devices have? | As of today, 908 Devices has over 71 employees. |
| Who is the CEO of 908 Devices? | 908 Devices' CEO is Kevin J. Knopp. |
| Is 908 Devices publicly listed? | Yes, 908 Devices is a public company listed on Nasdaq. |
| What is the stock symbol of 908 Devices? | 908 Devices trades under MASS ticker. |
| When did 908 Devices go public? | 908 Devices went public in 2020. |
| Who are competitors of 908 Devices? | 908 Devices main competitors include Profound Medical, Shoulder Innovations, Senseonics Holdings, Healius, Eurobio Scientific, Australian Clinical Labs, Zepp Health, Frontage Laboratories, Asterasys, TriSalus Life Sciences. |
| What is the current market cap of 908 Devices? | 908 Devices' current market cap is $265M. |
| What is the current revenue of 908 Devices? | 908 Devices' last 12 months revenue is $61M. |
| What is the current revenue growth of 908 Devices? | 908 Devices revenue growth (NTM/LTM) is 21%. |
| What is the current EV/Revenue multiple of 908 Devices? | Current revenue multiple of 908 Devices is 2.6x. |
| Is 908 Devices profitable? | No, 908 Devices is not profitable. |
| What is the current EBITDA of 908 Devices? | 908 Devices has negative EBITDA and is not profitable. |
| What is 908 Devices' EBITDA margin? | 908 Devices' last 12 months EBITDA margin is (14%). |
| What is the current EV/EBITDA multiple of 908 Devices? | Current EBITDA multiple of 908 Devices is (18.8x). |
| What is the current FCF of 908 Devices? | 908 Devices' last 12 months FCF is ($11M). |
| What is 908 Devices' FCF margin? | 908 Devices' last 12 months FCF margin is (18%). |
| What is the current EV/FCF multiple of 908 Devices? | Current FCF multiple of 908 Devices is (14.1x). |
| How many companies 908 Devices has acquired to date? | As of May 2026, 908 Devices has acquired 2 companies. |
| What was the largest acquisition by 908 Devices? | $54M acquisition of RedWave Technology on 30th April 2024 was the largest M&A 908 Devices has done to date. |
| What companies 908 Devices acquired? | 908 Devices acquired RedWave Technology and TRACE Analytics. |
| In how many companies 908 Devices has invested to date? | 908 Devices hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to 908 Devices
Lists including 908 Devices
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

